Abstract
The cost of drug discovery and development is driven primarily by failure, with just ∼10% of clinical programs eventually receiving approval. We previously estimated that human genetic evidence doubles the success rate from clinical development to approval. In this study we leverage the growth in genetic evidence over the past decade to better understand the characteristics that distinguish clinical success and failure. We estimate the probability of success for drug mechanisms with genetic support is 2.6 times greater than those without. This relative success varies among therapy areas and development phases, and improves with increasing confidence in the causal gene, but is largely unaffected by genetic effect size, minor allele frequency, or year of discovery. These results suggest we are far from reaching peak genetic insights to aid the discovery of targets for more effective drugs.
Competing Interest Statement
MRN and CLD are employees of Deerfield. MRN is an employee of Genscience. EVM and JP are consultants to Deerfield. EVM also acknowledges speaking fees from Eli Lilly, consulting fees from Alnylam, and research support, unrelated to the current work, from Ionis, Sangamo, and Gate.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
This manuscript has been extensively revised to improve clarity and address feedback. Changes include updating of OMIM and IntOGen data to latest available as well as additional analyses and figures to better describe the study, data, and results. None of the changes had a material impact on the results and conclusions.
Data Availability
All source code and data produced in the present work are contained in the supplementary material an online at https://github.com/ericminikel/genetic_support/
